Nearly 60 treatments completed since March 2026 at China's first medical institution delivering clinical BNCT with an overseas-approved drug-and-device combination. BOAO, China, Nov. 10, 2026 /PRNewswire/ -- Panboron BNCT, an oncology healthcare enterprise under China Biotech Services Holdings Limited (HKEX: 8037), today announced that international patients can receive boron neutron capture therapy (BNCT) at its Hainan hospital — the first medical institution in China delivering routine clinical BNCT care using a drug-and-device combination imported under the Boao Lecheng pilot zone's u…READ FULL ARTICLE
